Nexavar[®] (sorafenib) – Stivarga[®] (regorafenib): Improving survival in HCC



The most common form of primary liver cancer is hepatocellular carcinoma (HCC)¹

>841,000 cases of liver cancer are diagnosed each year²

2007

Sorafenib (marketed as Nexavar[®]) is approved for the treatment of certain forms of unresectable HCC.^{4,5}

75 - 85% of liver cancers worldwide are HCC³

4th leading cause


of cancer-related deaths globally³

Regorafenib (marketed as Stivarga[®]) is approved for the second-line treatment of patients with HCC who have been previously treated with sorafenib.^{6,7}

2017

Regorafenib for second-line HCC is recommended by clinical guidelines worldwide, including EASL* in Europe and the NCCN* in the U.S.^{8,9}

In the primary analysis of RESORCE, regorafenib significantly improved median OS (overall survival) in second-line HCC:



Results from the exploratory, retrospective analysis based on the **pivotal Phase III RESORCE tria** suggests that patients with advanced HCC treated with **sorafenib followed by regorafenib** had a median time from the start of sorafenib treatment to death of **26.0 months**, compared with **19.2 months** for those treated with **sorafenib followed by placebo.**¹¹

Safety Results: The safety and tolerability were generally consistent with the known profile of regorafenib.¹¹

The most common adverse events (grade 3 or greater) occurring more frequently in the regorafenib group included hypertension, hand-foot skin reaction, fatigue, hypophosphatemia, lipase increase, platelet count decrease and diarrhea.¹¹

*EASL - European Association for the Study of the Liver, NCCN - National Comprehensive Cancer Network

References: 1. American Cancer Society. Liver Cancer. 2019. Available at: www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html. Accessed August 2020. 2. GLOBOCAN 2018: Liver Cancer Factsheet. Available at: http://goo.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed August 2020. 3. Bray F, Ferlay J, *et.al.* Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Montality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/-caac.21492. Epub 2018 Sep 1. 4. Bayer HealthCare Pharmaceuticals Inc. Nexavar (Sorafenib). 2018. U.S. Food and Drug Administration website. Available at: www.accessedta.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf. Accessed August 2020. 5. European Medicines Agency. 2020. Nexavar: Product information. 2019. Available at www.accessedta.fda.gov/drugsatfda_docs/label/2017/203085bl.pdf. Accessed August 2020. 7. European Medicines Agency 2020. Storaga: Product information. 2019. Available at: www.accessedta.fda.gov/drugsatfda_docs/label/2012/203085bl.pdf. Accessed August 2020. 7. European Medicines Agency 2020. Stivarga: Product information. 2019. Available at www.ema.europa.eu/en/medicines/human/EPAR/nexavar. Accessed August 2020. 8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines. J Hepatol 2018;69:182–236. 9. National Comprehensive Cancer Network. NCCN Guidelines Version 5.2020. Hepatocellular Carcinoma. Available at: www.nccn.org/professionals/physician_gls/pdf/hepatobiliany.pdf. Accessed August 2020. 10. Bruix J, Qin S, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on strafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66. 11. Finn RS, Merle P, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018;69(2):353–358.